The panel integrates biomarker testing and digital tools to support fibrosis risk assessment and liver cancer surveillance.
Roche launched its Liver Disease Panel, a suite of certified algorithms designed to support clinicians in the identification and management of chronic liver disease (CLD). The panel combines biomarker-based diagnostics with digital algorithms to support clinical decisions ranging from fibrosis risk identification to liver cancer surveillance.
CLD affects an estimated 1.5 billion people globally, according to the press release. Many cases remain undiagnosed because early stages often lack symptoms, which can lead to cirrhosis, and liver cancer. Additionally, the prevalence of metabolic dysfunction-associated steatotic liver disease now affects 38% of the global population and is a fast-growing cause of liver cancer.
“Chronic liver disease impacts millions of lives around the world, and patients need effective care at every stage of their journey,” says Matt Sause, CEO Roche Diagnostics, in a release. “With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health.”
The suite integrates several tools into the navify Algorithm Suite, providing a single point of access for clinicians to order and view results. This includes LiverPRO, an algorithm that assesses liver fibrosis risk using patient age and at least three of nine common blood-based biomarkers. According to Roche, the panel “transforms the patient journey by enabling broader reach and timely patient detection through a scalable approach to assessing fibrosis severity.”
The panel also includes the ADAPT algorithm, which uses the Elecsys PRO-C3 biomarker to assess the severity of liver fibrosis. For hepatocellular carcinoma diagnosis, the panel utilizes the GAAD algorithm, which incorporates the Elecsys AFP and Elecsys PIVKA II biomarkers. Other integrated clinical tools include the FIB-4 Index, MELD Scores, ALBI Score, Child-Pugh Score, and the Lille Model.
The LiverPRO algorithm is CE-marked and has been endorsed in the European Association for the Study of the Liver patient trajectory guidance as a scalable first-line test for liver fibrosis. The tool is designed to standardize patient referrals and speed up the identification of high-risk cases using non-invasive technology.
ID 119859369 © Kowniewping | Dreamstime.com
